No Data
No Data
MediWound's (NASDAQ:MDWD) Investors Will Be Pleased With Their Stellar 125% Return Over the Last Year
Rosalind Advisors, Inc. Increases Stake in MediWound Ltd
H.C. Wainwright Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $28
Express News | Mediwound Ltd - Key Safety Endpoints Include Adverse Events and Wound Closure Time
Express News | Mediwound Ltd - to Initiate Phase II Study for Escharex in 2025
Express News | Mediwound Announces Phase II Head-to-Head Study Evaluating Escharex® Vs. Collagenase in Patients With Venous Leg Ulcers
No Data
No Data